These data confirm our previous results obtained in HCV patients with advanced hepatic fibrosis (F3–F4) and without T2DM who demonstrated an improvement in blood glucose and IR levels, as well as an improvement in pancreatic β‐cell function and insulin sensitivity.12 Current data were obtained on a larger population, which also included patients with F0–F2 liver fibrosis and patients with IFG and T2DM. The gene discussed is INS; the disease is type 2 diabetes mellitus.